Table 3.

Local treatment characteristics and toxicities

Local toxicity (patients, n)
Type of treatmentSitePatients (n)Single dose (Gy) median (range)Total dose (Gy) median (range)NoneGrade 1Grade 2Grade 3Grade 4ND
LPT (convent. radiation)Skin122.75 (1.8–3)41,25 (30–60)04 (33.3%)2 (16.7%)2 (16.7%)04 (33.3%)
Bone172 (1.8–4)44 (20–60)010 (58.8%)4 (23.5%)003 (17.6%)
LN (sf)142 (1.8–3)50.4 (30–60)3 (21.4%)4 (28.6%)3 (21.4%)3 (21.4%)01 (7.1%)
LN (deep)62 (1.8–3)50 (30–54)2 (33.3%)1 (16.7%)1 (16.7%)002 (33.3%)
Lung17 (na)35 (na)000001
Mediastinum32.2 (1.8–2.5)51 (36–56)01 (33.3%)1 (33.3%)001 (33.3%)
Liver12.5 (na)40 (na)100000
LPT (stereotacticradiation)Lung125 (na)25100000
Mediastinum117 (na)51100000
LPT (other)Liver (SIRT)1nana000001
Skin (ECT)4nana400000
CNS (radiation)Whole brain, conventional282 (2–4)30 (20–90)3 (10.7%)7 (25%)4 (14.3%)0014 (50%)
Local brain, stereotactic or cyberknife2720 (3–22)20 (18–60)26 (96.3%)00001 (3.7%)
  • NOTE: All local treatment types, including CNS radiation as non-LPT, that were applied to the patients during the study period are shown. Each treatment per body site and patient was analyzed separately. The patient numbers in this table do not sum up to the total count of the study population because some patients received more than one LPT during the period of analysis. Also, some patients treated with stereotactic CNS radiation received this treatment more than one time. Local radiotherapy toxicities were assessed according to the CTCAE version 4.03 and affected only the skin or mucosa.

  • Abbreviations: LN, lymph node; ND, no data available; sf, superficial.